1 Clovis Oncology, Inc. Data on File.2 Abida W, Armenia J, Gopalan A, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol 2017:1–16.

Mutation in either BRCA1, BRCA2 or ATM gene with tumors that can be seen and measured (visceral and/or nodal)

Primary endpoint = objective response rate (ORR) of tumors using RECISTv1.1 scoring method

Mutation in either BRCA1, BRCA2 or ATM gene with tumors that cannot be seen or measured

Primary endpoint = >50% decrease in prostate specific antigen (PSA) levels in the blood

Mutation in another gene that gives rise to sensitivity to PARP inhibition with or without measurable disease

Primary endpoint = ORR assessment if measurable or PSA response if not

• Confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate

• Surgically or medically castrated with testosterone levels of ≤50 ng/dL (1.73 nM)

• Disease progression after prior therapy for mCRPC, including treatment with one or two prior next-generation androgen receptor-targeted therapies, and treatment with one prior taxane-based chemotherapy

• No prior treatment with any PARP (poly (ADP-ribose) polymerase) inhibitor, mitoxantrone, cyclophosphamide, or any platinum-based chemotherapy

• No symptomatic and/or untreated central nervous system (CNS) metastases or active secondary malignancy

Rucaparib is an oral, small-molecule PARP inhibitor. TRITON2 is a Phase 2, open-label, international study investigating the effect of rucaparib treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA gene mutation (inclusive of germline or somatic) and also enrolling patients with deleterious mutations of other homologous recombination (HR) repair genes, including ATM. All patients must have progressed following at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy.1

Trial Schema

THE TRITON2 CLINICAL TRIAL

HR status assessed by either:• Plasma ctDNA• Archival tumor DNA, or• Screening tumor DNATo determine deleterious somatic or germline mutation in BRCA1, BRCA2, ATM or other HR gene

Rucaparib 600mg BID all cohorts

Progression or discontinuation for other reason

• Follow-up at 28 days• Long-term follow-up: • Tumor assessments every 8–12 weeks if yet to progress • Patients followed every 12 weeks to check survival, subsequent survival and secondary malignancies

SCREENING TREATMENT POST-TREATMENT

A B C

Key Eligibility Criteria

Study Cohorts and Endpoints

More information on this trial (NCT02952534) is available at ClinicalTrials.gov and www.tritontrials.com

Approximately 12% of mCRPC patients

have a deleterious mutation in BRCA1 or BRCA2.2

NP-CLVS-ALL-0006Date of Preparation: September 2018